Internet Drug
Pharmaceutical News & Information; Updated Daily Since 1998

Drug Coupons Database
Medical Dictionary
Clinical Trials In Progress
Clinical Trial Results
SEARCH Medline
Medline Plus  by Topic
Gen Info;Site Dissection

Boiler Plate Patient Info
Advisory Documents
Database Of Ongoing Clinical Trials
New Drug
Dear Doctor Letter Database
Drugs@FDA [gateway]
Drug Approvals Report

Newly filed ANDA's
Product Data Database
Orange Book
Recently Approved Drugs (CenterWatch)
Upcoming Meetings

Medwatch Safety
NDC Code Directory

Postmarketing Safety Data

Warning Letters
Medwatch Top Pages
Site Map
Pharmaceutical Sales
Diabetes Drugs
Drug Information Databases
Pharmaceutical Sales

Search By Definition

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here

Worth a Click:
- PharmaGossip
- Viagra For Women; Investigative Report
- Patent Docs
- Medical Media & Marketing News
NEW - Farmazia.Net (Spain)
- Canada Pharmacy News
- Drug Wonks
- World Of DTC
¿Your Link Here?
Let's Trade

Pharmaceutical News Harvest (TM)

2/5 Senators' Holds on Califf Finally Get FDA to Revisit Opioid Policy
FDA Will Act on Pain Pill Abuse After Senate Blocks Nominee .... Opioid addiction has become a major issue in the presidential race, at the White House and in Congress, where Robert Califf, President Barack Obama's nominee to head the FDA, has been held up in the Senate because of concerns about how the epidemic is being handled .... Bloomberg

2/5 Stem Cell Treatment Cures Diabetes in Animals; Now in Human Tests
Johnson & Johnson, ViaCyte testing possible diabetes cure .... The therapy involves inducing embryonic stem cells in a lab dish to turn into insulin-producing cells, then putting them inside a small capsule that is implanted under the skin. The capsule protects the cells from the immune system .... AP

2/5 Cognitive Dysfunction in Major Depressive Disorder is Now a Thing
FDA Advisors Support New Indication for Brintellix .... Panelists who voted to approve the indication said the data presented by drugmaker Takeda from two clinical trials showed a small effect on cognition, but this was at least a step toward mitigating an unmet need in depression .... Medpage Today

2/5 Trulicity Pulling Share from Victoza
Novo Nordisk Quarterly Profit Misses Estimates on Victoza .... Victoza, injected daily to mimic the activity of a hormone called GLP-1 that stimulates insulin production, showed the first signs of suffering from the introduction of a rival product called Trulicity by Eli Lilly that only requires a weekly injection .... Bloomberg

2/5 Updated Adult Immunization Schedule
ACIP Approves 2016 Adult Immunization Schedule .... The major changes to the schedule relate to human papillomavirus (HPV), pneumococcal, and serogroup B meningococcal (MenB) vaccines .... HealthDay News

2/5 More than Lip Service: Drug Companies Making Serious Investment in Adherence
Big Pharma's big push to get patients to take their meds .... GlaxoSmithKline has enrolled 3,000 of its employees, retirees, and their family members in North Carolina in a pilot program to better coordinate their health care. Among other things, it uses sophisticated analytics to determine who's not sticking with their medication .... Stat

2/5 New Valeant CEO Wants to Bring Copay Coupons to Medicare
Valeant chief calls on Medicare to allow controversial copay help from pharma .... Copay coupons for patients in Medicare and other government-funded healthcare programs are currently considered an illegal kickback under federal law, forcing drugmakers to limit their assistance to those with commercial insurance .... Fierce Pharma

2/5 Shkreli/Pharma Congressional Hearing Was Amusing Til You Remember These People are Making Life and Death Decisions
Valeant, Turing Slammed as Shkreli Calls Congress 'Imbeciles' .... The hearing in Washington was heated and at times a puzzling spectacle, with controversial pharma executive Martin Shkreli smirking throughout but refusing to testify after invoking the Fifth Amendment, his lawyer being asked at one point to stay seated, and Shkreli later taking to Twitter to insult lawmakers .... Bloomberg (link includes autoplay video highlights)

2/5 Benzodiazepines Off the Hook
Anxiety Meds Valium, Xanax And Ativan May Not Lead To Dementia .... The highest doses of benzodiazepines--use of the drugs daily for a year--were not linked to any increased risk for dementia. Oddly, low and moderate doses (up to one month, or four months, respectively) were linked to a slightly increased risk .... Forbes/Alice G. Walton

2/5 Pfizer Has Vaccinated About a Third of Those Eligible for Prevnar in US
Prevnar's 2015 sales surged to $6B-plus on new CDC nod in adults .... Though prices in Europe are much lower than they are in the U.S., there's a much larger group of eligible adults to draw from, and Pfizer is working to snag favorable reimbursement recommendations from authorities across the continent .... Fierce Pharma Marketing

2/5 Internet Drug News Fast Takes:
CDC: Women who don't use birth control shouldn't drink
Advisory Board Daily Briefing
Hospitals can be 'urban' and 'rural' at same time: U.S. appeals court
Scientists Use Infrared Light to Measure Blood Glucose
FDA Approves Merck's Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)
Company news release
Depomed Wants to Block FDA Approval of Nucynta Generics
Bloomberg BNA

2/4 Here are 2016's Blockbusters
Seven $1 billion-plus drugs seen reaching market in 2016 .... The two top hits of 2016 are tipped to be Intercept Pharmaceuticals' chronic liver disease drug obeticholic acid, with a consensus sales forecast of $2.6 billion in 2020, and Gilead Sciences' new fixed dose HIV drug emtricitabine plus tenofovir alafenamide, on $2.0 billion .... Reuters

2/4 How Valuable Can This Doc Be for Your Brand? Zephyr Says it Knows
The Startup Tracking 'Valuable' Doctors for Big Pharma .... Gathering various strands of information, Zephyr generates profiles that score each doctor's influence and ability to drive sales on a scale of 1 to 10. The software's slick, mobile-friendly interface lets a drug company search in broad or specialized disciplines (from "oncology" to "non-Hodgkin lymphoma") and ranks each person's influence in the chosen field .... Bloomberg

2/4 The 'Foot in the Door' Gets Harder and Harder
4 industry vets sound off on the state of physician-rep access .... Although access has improved, it has done so at the expense of additional restrictions.... the percentage of physicians requiring appointments or restricting access to certain hours has increased more rapidly and is at a three-year high .... MM&M

2/4 Januvia Off Target; Keytruda and Zetia Save Merck's 4Q
Merck's Top-Selling Diabetes Drugs Miss Sales Estimates .... The diabetes pill Januvia is Merck's top-selling product, and sales of $1.44 billion for that drug and another formulation, Janumet, fell short of estimates for $1.67 billion .... Bloomberg

2/4 Nobody Wants to Hear About Your Disease at a Superbowl Party
NFL games are magnets for drug ads. But the Super Bowl isn't. Here's why .... In the lighthearted atmosphere of the Super Bowl, it's an uphill battle to produce a successful ad about a serious health condition .... Stat

2/4 ACCORD Trial Long-term Follow-up
Neutral Long-Term Effect for Intensive Glycemic Control .... The researchers found that a mean of 3.7 years of intensive glucose lowering had a neutral long-term effect on the primary composite outcome (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular disease), death from any cause, and an expanded composite outcome that included all-cause death .... HealthDay News

2/4 Eliquis Sales Doubled Since Last Year; BMS Wants #1 Position
BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa .... Bristol isn't planning to let up on any of the increased spending that helped Eliquis make big gains last year. The company began its DTC efforts in September of 2013, a year in which Q4 Eliquis revenues tallied just $48 million .... Fierce Pharma Marketing

2/4 Ruckus Over Flooding Living Room Heart Failure Ad
Entresto Maker In Deep Water Over Terrifying TV Advertisement .... The ad depicts a middle-aged man in an easy chair reading the newspaper, oblivious to a rising flood that threatens to drown him, though his dog, climbing onto a couch for safety, expresses considerable anxiety .... Cardiobrief

2/4 TrusTED Wants to Put FDA Approvals Up to a Congressional Vote
Sen. Ted Cruz Wants To Change The Way The FDA Approves Drugs .... The RESULT Act would allow for reciprocal approval of drugs, devices and biologics from foreign sponsors in European countries, as well as from Japan, Canada, Australia and Israel. In addition, the bill would allow Congress to overrule FDA rejections of life-saving drugs with a majority vote via joint resolution .... Forbes/John LaMattina

2/4 Viewability Pow-Wow Feb. 4
Pharma, ad agencies press publishers for higher ad viewability standards .... The Internet Advertising Bureau now recommends that 70% of the ad be visible for one second, while individual brands and agencies are pushing for even more, usually 100%. .... Fierce Pharma Marketing

2/4 Internet Drug News Fast Takes:
18 cities in Pennsylvania reported higher levels of lead exposure than Flint
CVS Pharmacy makes Target debut
Chain Drug Review
Cancer drug testimonials tinged with financial interest
Milwaukee Journal-Sentinel
Smart Band-Aid on the Horizon
NY Times
Old Novartis cancer flagship Gleevec heads to pharmacies as lower-cost generic

2/3 Cleveland Clinic Has a Full-Time Pharmacist Dealing with Drug Shortages
Drug Shortages Forcing Hard Decisions on Rationing Treatments .... Such shortages are the new normal in American medicine. But the rationing that results has been largely hidden from patients and the public .... NY Times

2/3 Drug Price Boosts Most Common at End and Beginning of the Year
Shkreli Was Right: Everyone's Hiking Drug Prices .... A survey of about 3,000 brand-name prescription drugs found that prices more than doubled for 60 and at least quadrupled for 20 since December 2014 .... Bloomberg

2/3 Internal E-mails Show Turing Execs Cackling Over $7.2 Million Purchase Orders for Daraprim
Martin Shkreli All but Gloated Over Huge Drug Price Increases, Memos Show .... Martin Shkreli anticipated huge profits from raising the price of Daraprim, belying any notion that helping patients was foremost in his minds .... NY Times

2/3 Baby Powder Link to Cancer?
J&J's Talcum Powder Goes on Trial in Ovarian Cancer Lawsuits .... The world's largest maker of health-care products faces accusations by the family of a woman who died that it knew decades ago that talc, the Earth's softest mineral, was linked to ovarian cancer .... Bloomberg

2/3 Brintellix Tries for New Indication: Confused Thinking Tied to Depression
This antidepressant may be no better than cheaper alternatives. But demand could soon soar .... The drug makers behind Brintellix are betting they can give it a boost by marketing it to treat a whole new category of depression symptoms -- namely, cloudy thinking. .... Stat News

2/3 Ketamine Now Mainstream; Boasts 75% Success Rate
Onetime party drug hailed as miracle for treating severe depression .... A growing number of academic medical centers, including Yale University, the University of California at San Diego, the Mayo Clinic and the Cleveland Clinic, have begun offering ketamine treatments off-label for severe depression, as has Kaiser Permanente in Northern California .... Washington Post

2/3 His Life Mission: End Drug Patents
Big Pharma's worst nightmare .... Jamie Love has spent years battling global drug companies, unshakable in his belief that even the world's poorest people should have access to life-saving medicines .... The Guardian

2/3 "Three is the magic number for payers to get more aggressive": PBMs Holding Fire on PCSK9 Inhibitors
With PCSK9s, payers say, 'Let the market decide' .... Several months after introduction many payers haven't yet anointed one PCSK9 over the next. Nor have they publicly taken the makers to task over pricing, positioning or anything else .... MMM-Online

2/3 Pfizer Stops Trial; Wall Street Sells Off Related Drug
Pfizer Halts Drug Trial, Investors Flee Axovant .... Pfizer discontinued the PF-05212377 (also known as SAM-760) trial in October of 2015 but only updated the NIH's listing on February 2, making the futility discontinuation public knowledge .... Forbes/Jake King

2/3 Insulin Prices Up 20% in One Year
Patients shocked as insulin prices climb higher .... Express Scripts, the largest U.S. pharmacy-benefit manager, said the price of two prominent brand-name injectable insulins, Lantus and Humalog, rose 22.7 percent and 19.9 percent, respectively, from 2014 to 2015. .... Medical Xpress

2/3 Internet Drug News Fast Takes:
Sanofi launches hunt for Zika vaccine as disease fears grow
Abbott plunges deeper into diagnostics with $5.8bn Alere buy
Pharma Times
Andreessen Horowitz Wants To Bring Biology To The Cloud
Forbes/Steve Dickman
Empliciti on track for European approval in multiple myeloma
Researchers Say JNC8 Recs May Put Some Patients at Risk
HealthDay News

Fast Takes
CVS To Sell Overdose-Reversing Drug Without  Prescription In Ohio
CVS Press Release
Hospital fined $86K after surgeon leaves towel inside patient
Brain's Capacity Is 10 Times Greater Than Previously Thought
Dr Reddy Gets Tentative Nod For Generic Oracea (Doxycycline Caps 40 mg)
Dr Reddy Press Release
Study finds Pfizer's Chantix is no better than nicotine patches
Gilead accused of gaming HIV Drug patents
Don't expect a generics-style smackdown from Remicade biosims, J&J CEO says
Fierce Pharma

2/2 Hillary Campaign Sidesteps Generic Price Increases
Clinton's Price-Gouging Complaint Sidesteps Generic Drug Problem … fewer than 100 prescriptions for Valeant's branded migraine drug in 2015, versus more than 40,000 for generic versions … Thousands use Perrigo generic whose cost has tripled since '11 … now costs $600 a carton …[Bloomberg]

Oxycontin Patents Struck Down Clearing Way For Generics
- Only authorized generics are available presently
U.S. appeals court ruling may clear barrier to generic OxyContin … Currently, the only generic versions of OxyContin on the market are so-called "authorized generics … four patents related to Purdue Pharma's painkiller OxyContin are invalid, potentially bringing Teva Pharmaceutical Industries Ltd and others a step closer …[Reuters]

More Insurance Companies Report Losing Money On Obamacare
More ObamaCare Losses … UnitedHealth recently reported that it may lose $1 billion  … Aetna is worried about 'the …  easy for customers to wait until they were sick to buy insurance. This stocks the risk pool with sicker people and disrupts actuarial calculations….[WSJ]
Aetna Has 'Serious Concerns' With ObamaCare Exchanges … [Investor's Business Daily]

2/2 AbbVie Lowers Sales Forecast For Humira and Viekira Pak
- Biosim Enbrel® (etanercept), Merck Hep C Pill to dent sales of cash cows
AbbVie shares fall on sales outlooks for Humira and Viekira Pak …  growth of Humira outside the United States will likely slow … cited competition from a cheaper biosimilar form of rival arthritis drug Enbrel … competition from Merck's Zepatier hepatitis C drug …[Reuters]

Fast Takes
Weed-infused 'female suppositories' for vaginal cramps are a thing now
How did doctors treat infections before antibiotics?
3 Key FDA Decisions Expected in February
247 WallStreet
Novartis blames slower-than-expected Entresto growth in US on insurer tardiness
HIV Growing Resistant to Common Treatment Tenofovir
Drug Developmenmt & Discovery

2/1 China: 100 Million Diabetics; $23 Billion Market Waits To Be Tapped
China's diabetes boom promises $23 billion pot for drug makers … Only 15% of those diagnosed are receiving treatment. … More than 100 million people have diabetes in China, more than any other country in the world … market for diabetes drugs in China is as big as the entire populations of Australia, Canada and Argentina -- combined … [Marketwatch]

Pharma In Presidential Cross Hairs No Matter Who Wins
- Strong consensus to negotiate Medicare drug prices
Presidential Candidates & Rx Policy … Clinton … denying tax breaks for direct-to-consumer advertising … cap monthly and annual out-of-pocket costs for prescription drugs" … Sanders' primary lever in achieving his goals re: the Rx industry is doing away with the prescription drug "non-interference policy" in the Medicare Part D … Ted Cruz, has avoided discussion drug price issue …[Pharmaceutical Executive]
Trump calls for Medicare to negotiate drug prices … broken from Republican orthodoxy on one other major healthcare policy this campaign, defending his past support for single-payer healthcare, long a dream of liberals … [The Hill]

Tresiba Claima Lower Hypoglycemia Than Lantus
Tresiba: Lower Rate of Hypoglycemia Than Insulin Glargine In Phase 3b Trial … severe hypoglycemia was 186 events per 100 patient years exposed to Tresiba and 265 events per 100 patient years exposed to insulin …  reduction of 30% when people were treated with Tresiba compared to insulin glargine … [DrugDiscovery & Development]

Gliead CEO Steps Down Unexpectedly
Gilead CEO to step down amid drug price debates … served as CEO since 1996, a year when the company's total market valuation, about $1 billion … drugs [Harvoni and Solvaldi] are projected by analysts to have sold $18.8 billion in 2015…[Boston Globe]
Gilead CEO John Martin Is Stepping Down After 20 Years …  stock dropped more than 5% following the announcement … mounting investor pressure. Martin had abstained from dealmaking during the pharma industry's M&A frenzy in the last few years …[Fortune]

Merk Hep C Pill Will Be $40K Cheaper Than Harvoni, $30K Cheaper Than AbbVie Pill
Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie … As part of a pricing war, both companies have struck deals with payers that offer substantial discounts, and Merck said it believes its newcomer is "in the range" with those products when it comes to their net price …[Fierce Pharma; Carly Helfand]

Allergan Depression Injection Bags 6-Month Review
Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder (MDD) … preliminary clinical evidence for rapastinel, which supports a rapid (within 1 day) and sustained antidepressant effect … nvestigational intravenous formulation of a novel NMDA receptor partial agonist, which is being evaluated for adjunctive treatment of MDD, and has shown a rapid onset of antidepressant efficacy 1 day after a single dose  …[Allergan Press Relese]

Express Blocks Valeant 's Wildly Overpriced Metformin Pill
Express Scripts Blocks Valeant Diabetes Drug in Cost Fight … Valeant raised the price of Glumetza by 800 percent in 2015, said Express Scripts. The drug now retails for about $1,500 a month … To protect our clients and patients from wasteful, unnecessary drug spend, Express Scripts will exclude Glumetza … [Bloomberg]

2/1 FDA finds Indian drug maker Wockhardt hid failed tests
FDA finds Indian drug maker Wockhardt hid failed tests … atest of several major players in the $15 billion Indian drugs industry to be hit by U.S. regulatory action over the past few months…. audit showed that the results of 22 failed tests had not been recorded. It also found multiple data files had been deleted from some machines….[Reuters]

P.A. Pay Increases Dramatically
Physician Assistant Pay Reaches $100K Annually … PAs in California, Connecticut, Minnesota, Arizona and Alaska have a median salary of $105,000 … six-figure PA salary contrasts to just a few years ago when they were making $87,000 in 2010 and $71,000 in 2001
Physician assistant … 22% of them can speak to their patients in a language other than English … Most have a two-year master's degree …[Forbes]
Prediction: $100K after a 2 year master's degree is great Pay.  Few other 2 year post grad degrees pay as well.  I predict that PA school will go to a 3-year program just as pharmacy morphed from a 5 year program to a 6 year program.

1/29 Zepatier OK'd
FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4 .... The overall sustained virologic response rates ranged from 94-97 percent in genotype 1-infected subjects and from 97-100 percent in genotype 4-infected subjects across trials for the approved treatment regimens ....

1/29 Halaven Approved for Liposarcoma
FDA approves Eisai's drug Halaven for type of soft tissue cancer .... FDA has approved Eisai's drug derived from sea sponge for a rare type of soft tissue cancer which has no approved treatment so far .... Reuters

1/29 Adzenys XR-ODT, Long-acting ADHD Treatment
FDA approves Neos Therapeutics' long-acting ADHD drug .... The drug, Adzenys XR-ODT, is approved for the treatment of Attention Deficit Hyperactivity Disorder in patients aged six and older. The drug is an orally disintegrating tablet and a longer-acting version of amphetamine, a commonly prescribed ADHD drug .... Reuters

1/29 Roche Head Says Drug Prices in U.S. Will Be Driven Down, But 'Not Our Cancer Drugs'
Roche expects cancer treatments to be spared U.S. pricing curbs .... U.S. prices for the world's 20 top-selling medicines are, on average, three times higher than in Britain .... Reuters

1/29 Opdivo, Eliquis Drive BMS Earnings
Bristol-Myers Beats Estimates on Key Cancer Drugs .... Bristol-Myers is benefiting from its focus on oncology, after introducing high-priced therapies like Yervoy and Opdivo, which harness the body's immune system to fight the disease .... Bloomberg

1/29 Payer Footdragging = Slow Start for Entresto
Novartis says slow Entresto sales due to limited access .... Forty-four percent of Medicare patients and 57% of commercial insurance patients have access to Entresto, and 26% of Medicare patients and 21% of commercial insurance patients can access the medication with lower co-pays .... Bloomberg

1/29 Jakafi No Help for Colorectal Cancer
Incyte stops tests on Jakafi to treat colorectal cancer .... Incyte was testing Jakafi in combination with Bayer AG's Regorafenib to treat metastatic colorectal cancer, in which diseased cells break away from the colon or rectum and spread to form tumors on other organs. .... Reuters

1/29 Double-Acting PPI
Dexlansoprazole (Dexilant) Soluble Tablets Win FDA Nod for GERD-Associated Heartburn .... Dexilant SoluTab is a PPI with dual delayed-release technology that is designed to provide two separate releases of medication .... PTCommunity

1/29 Three Lots of Lyrica Recalled
Recalled Lyrica Damaged By 'Extreme Heat' .... Nearly 150,000 bottles of Lyrica are being recalled by Pfizer in the United States and Puerto Rico because they may have been damaged by "extreme heat" while being transported .... Pain News Network

1/29 Tecfidera Sales Up on TV Ads But Also 28% Price Hike
Tecfidera's DTC campaign boosts Web traffic and call volume .... Overall, Tecfidera brought in $3.6 billion last year--$2.9 billion of which was from the US. The drug's total sales were $2.8 billion in 2014. Tecfidera is the most commonly prescribed oral MS drug .... MM&M Online

1/29 Internet Drug News Fast Takes:
Scientists open the 'black box' of schizophrenia with dramatic genetic discovery
Washington Post
Viral infection during pregnancy causes autism-like behaviors in mice
University of Massachusetts Medical School
Redwood City opens food pharmacy for low-income diabetes patients
US breakthrough status for AstraZeneca, AbbVie drugs
Pharma Times
Hepatitis C Reported at 19 Dialysis Clinics: CDC

1/28 Massachusetts Threatens Lawsuit Over Sovaldi/Harvoni Prices
Massachusetts Attorney General calls on Gilead to lower price of hepatitis C medicines .... In a letter to Gilead chief executive John C. Martin, the attorney general wrote that the high price of the company's Sovaldi drug, which cost $84,000 for a full course of treatment, and its Harvoni drug regimen, which cost $94,500, "may constitute an unfair trade practice in violation of Massachusetts law." .... Boston Globe
See also: The AG of Massachusetts Has No Chance Against Gilead [In the Pipeline/Derek Lowe]

1/28 Biotech Closely Watches CRISPR IP Tug-of-War
The Battle Over CRISPR Could Make Or Break Some Biotech Companies .... Without licensing from the eventual winner of the patent fight, Editas and other companies investing in commercial CRISPR research could be blocked from marketing products based on the intellectual property in question, putting at risk hundreds of millions of dollars in investment .... Five Thirty Eight

1/28 Jimenez Says Pricing Power Gone in the US
Novartis Chief Sees Lasting Price Pressure as the New Reality .... Novartis, the maker of the blockbuster cancer drug Gleevec, is responding to the expected pressure by pooling its manufacturing operations to cut costs .... Bloomberg

1/28 "Unicorn" Lab Start-up Gets Life-Threatening Wound
Theranos Lab Faults Jeopardized Patient Health, U.S. Says .... Theranos violated at least five regulations governing clinical laboratories that operate medical diagnostics used to do things like test blood levels or assess disease .... Bloomberg

1/28 NICE Recommends Biosimilars
Biosimilar drugs get boost as UK cost agency backs their use .... So-called biosimilars are gaining ground in Europe, which has been faster to adopt their use than the United States, offering savings to healthcare systems and threatening sales of companies making original products .... Reuters

1/28 Just 40% of Girls and 21% of Boys in the U.S. Have Gotten HPV Vaccine
Cancer Centers Urge Increase in HPV Vaccinations .... Joint statement calls for all boys and girls to complete the three-dose vaccination by their 13th birthdays .... WSJ$$

1/28 If for Some Reason You Want More Shkreli, Here You Go
Why Is Martin Shkreli Still Talking? .... He insists, though, that his own bad reputation is just that--a rep--and that the feds won't find anyone he's actually harmed .... Vice

1/28 Patient Support Programs in "Early Innings"
J&J CEO: Patients have higher expectations .... J&J's orthopaedic and neurosurgery devices arm, DePuy Synthes, has launched a support program that includes a subscription-based software service aimed at allowing providers to more easily collect data on patient outcomes, patient satisfaction and the costs of care in outpatient services .... MM&M

1/28 Pain Panel That Blasted CDC Recommendations Full of Ties to Drugmakers
Federal pain panel rife with links to pharma companies .... Nearly a third of members on the Interagency Pain Research Coordinating Committee have financial connections to makers of opioid drugs like OxyContin .... AP

1/28 J&J Spent $101 Million on Invokana Ads in 2015 — And Sales More than Doubled
New brands, stepped-up spending drive big TV-ad outlay for diabetes in 2015 .... New medicines, along with increased marketing budgets on older meds, more than doubled diabetes category spending on TV advertising in 2015 to $468 million, up from $194 million in 2014 .... Fierce Pharma Marketing

1/28 Internet Drug News Fast Takes:
Four Zika cases found in New York among returning travelers
Topokine Initiates Phase 2 Trial of TAT4 Gel for Topical Reduction of Laugh Lines
Company news release
These Fraudsters Say They Broke Into Fitbit Accounts Using Passwords Bought For 50 Cents
Buzzfeed News
U.S. to Halt Blood Donation by Travelers to Areas With Zika
One percent of U.S. docs responsible for a third of malpractice payments

1/27 Trump: I'll save $300 billion a year making Medicare negotiate
Trump backs Medicare negotiating drug prices .... The Associated Press quotes Trump as telling a crowd in Farmington, N.H., that Medicare, a huge buyer of prescription drugs, could "save $300 billion" a year if it negotiated discounts .... Politico

1/27 No Way to Beat the Inhaler Meter
Spiriva -- Half the Medicine Provided is Wasted .... The company manufactures only one size of canister but sells two different inhaler mechanisms. One delivers two-weeks-worth of medicine (28 puffs) and the other four-weeks-worth (60 puffs). So basically, the two week version is overfilled, and half the medicine goes to waste .... Mouseprint

1/27 Zika Panic Hitting Fever Pitch
U.S. boosts study of Zika, birth defect link, as virus seen spreading .... The U.S. Director of the National Institutes of Health called for intensified efforts to study the impact of Zika infections, citing a recent study estimating the virus could reach regions where 60 percent of the U.S. population lives .... Reuters

1/27 Senators Lining Up to Block Califf
Three senators now holding up FDA nominee -- for three different reasons .... Sanders' reason: Califf's "close ties to the pharmaceutical industry and lack of commitment to lowering prices." .... Washington Post

1/27 Big Data, Big Cloud, Internet of Things: Technology Hype Cycle Building
Big Pharma's bet on Big Data creates opportunities and risks .... This kind of new medical technology is designed to allow patients to keep track of their drug usage on their smartphones or tablets and for their doctors to instantly access the data over the web to monitor their condition .... Reuters

1/27 AFIB Feels Like a Fish Fluttering in Your Chest; BI Uses Fish Image for Ads
Fishing for market share, Boehringer Ingelheim casts a new campaign for Pradaxa .... The red CGI fish serve as representations of red blood cells as they move--and sometime clot--when traveling between the heart and the brain. The work is meant to educate patients with AFib about their greater risk of stroke .... Fierce Pharma Marketing

1/27 J&J 4Q 2015 in Line with Expectations
Drug Sales Are Driving Johnson & Johnson's Growth .... Drug sales account for about 45% of total revenue and have grown nearly 9.6% annually since 2010 .... Fortune

1/27 Payer Contracts Key to Tresiba Success
Novo Nordisk rolls out long-awaited Tresiba, aiming for blockbuster U.S. market share .... Tresiba lasts 42 hours and has a "flat and steady profile" that allows patients to dose at any time of day. The company is still negotiating with most payers, but it has struck a deal with CVS Health for its lowest copay tier for branded meds .... Fierce Pharma

1/27 Feds Lay Out Average Manufacturer Price (AMP) Model
Industry eyes CMS final rule for Rx reimbursement .... Among core elements of the 658-page final rule is a regulatory definition for AMP, which CMS said is the Medicaid drug rebate program’s key metric both for determining manufacturer rebates and pharmacy reimbursement for certain generics subject to the Federal Upper Limit .... Chain Drug Review

1/27 LixiLan is New Type of Combo for Diabetes
Diabetes R&D narrows in on glycemic control .... Sanofi's most recent foray in the arena, provided it gains FDA's nod of approval, will be the first to combine a basal insulin (with proven cardiovascular safety) with a GLP-1 receptor agonist (ditto) in a single daily injection .... MM&M

1/27 Internet Drug News Fast Takes:
Universal Depression Screening Urged
Medpage Today
Patients who are not prescribed opioids find more improvements in physical function
Medical Xpress
Anti-asthma drugs taken during pregnancy associated with autism risk
Drexel University
Is There Hope For Sarepta Therapeutics? Yes, A Bit
Forbes/Matthew Herper
A Conversation with George Barrett, Cardinal Health
Pharmaceutical Commerce

Site Map | Privacy Policy | Contact Webmaster
Site Mission Statement, Intended Audience, Editorial Policy, Advertising Policy
This Page Last Updated 2/1/16

If you feel that your intellectual property being infringed
e-mail the webmaster and we will remove the content. 

The information on this site is not meant as medical advice.  Information provided on the site is meant to complement and not replace any advice or information from a health professional.

I am not a doctor - I am a pharmacist.  If you have any medical questions please consult your medical doctor or similar medical practitioner. 

We never answer drug or health related questions so please don't e-mail us with your drug related questions. 

If you have a question about a drug that you are taking or if you think you are experiencing a side effect from a drug that you are taking you must get in touch with the doctor who prescribed the drug or the pharmacist who dispensed it to you, not us.

The information contained on this web site is for your information only.  You should never take a drug without a doctor's prescription.   Do NOT give yourself any drug unless it has been prescribed for you by a doctor.

It's foolish to start taking a medicine or stop taking a medicine on your own based on information you read here or any other internet web site because this could cause you to become seriously ill or die or worse even.


Corey Nahman Licensed Pharmacist (State Of NY; Lic #035512)

We subscribe to The HONcode of  online conduct:

1.  Qualification of author(s)
This site is published and webmastered by Corey Nahman, Registered pharmacist in the Sate of New York.
2.  Complementarity
Let it be known that the information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
3.  Privacy.
We respect the privacy of the users of this site.  Please see our plain English privacy policy.
4. Attribution
At all times, the information on this site shall be footnoted with the source(s) of published information, date and medical and health pages provided.
5.  Justifiability
This site shall at all times back up claims relating to benefits and performance.
6  Transparency
This site shall at all times use accessible presentation, you can e-mail the publisher of this site at his personal e-mail address at any time.
7.  Financial disclosure
This site is supported by click advertisements, banner advertisements and affiliate arrangements.  All ads are properly labeled as such.  If you have any questions regarding how we make money please e-mail the webmaster with your questions.  All advertisements shall be clearly distinguished from content.

Badea, Badea, Badea,
That's All Folks!